UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 69

Sortiert nach

FDA PATIENT-REPORTED OUTCOME LABELING OF NOVEL THERAPIES (2011-2015)

Value in health, 2016-05, Vol.19 (3), p.A285-A286

2016

Link zum Volltext

Verfügbarkeit prüfen

United States decision maker perceptions of data from observational studies and other Health Economics and outcomes research

Value in health, 2015-05, Vol.18 (3), p.A75-A75

2015

Link zum Volltext

Verfügbarkeit prüfen

Evidence-Based Medicine, Appropriate-Use Criteria, and Sports Medicine: How Best to Develop Meaningful Treatment Guidelines

Arthroscopy, 2013-07, Vol.29 (7), p.1224-1229

2013

Link zum Volltext

Verfügbarkeit prüfen

PNS226 A CONSOLIDATED FRAMEWORK FOR COLLABORATION IN RWE GENERATION FOR A MEDICAL PRODUCT

Value in health, 2019-05, Vol.22, p.S324-S324

2019

Link zum Volltext

Verfügbarkeit prüfen

PCR74 Trends in the Inclusion of Patient Reported Outcomes in Oncology Clinical Trials: Analysis of ClinicalTrials.gov (2013-2022)

Value in health, 2023-06, Vol.26 (6), p.S325-S325

2023

Link zum Volltext

Verfügbarkeit prüfen

PRM111 Pediatric Patient-Reported Outcomes Assessment: A Case Study in Epidermolysis Bullosa

Value in health, 2012-11, Vol.15 (7), p.A480-A481

2012

Link zum Volltext

Verfügbarkeit prüfen

Payer Needs In Emerging Markets: How Should These Needs Be Included In Dermatology Drug Development Plans?

Value in health, 2014-05, Vol.17 (3), p.A290-A290

2014

Link zum Volltext

Verfügbarkeit prüfen

“Safe And Effective” Versus “Reasonable And Necessary”: Is The Deck Stacked Against Devices?

Value in health, 2013-05, Vol.16 (3), p.A246-A246

2013

Link zum Volltext

Verfügbarkeit prüfen

Psychometric Evaluation Of The Patient's Knee Implant Performance (PKIP) Questionnaire For The Assessment Of Primary Total Knee Arthroplasty

Value in health, 2014-11, Vol.17 (7), p.A568-A568

2014

Link zum Volltext

Verfügbarkeit prüfen

PHP182 Concordance of PRO Labeling Claims Between the FDA and EMA

Value in health, 2012-11, Vol.15 (7), p.A321-A321

2012

Link zum Volltext

Verfügbarkeit prüfen

Psychometric Evaluation Of The Psoriasis Symptom Diary Using Phase 3 Trial Data

Value in health, 2014-05, Vol.17 (3), p.A288-A288

2014

Link zum Volltext

Verfügbarkeit prüfen

PIH53 Assessment of PRO Labels Claims Granted by the FDA as Compared to the EMA

Value in health, 2012-06, Vol.15 (4), p.A201-A201

2012

Link zum Volltext

Verfügbarkeit prüfen

PIH49 Patient Reported Outcomes as Primary Endpoints in Confirmatory Clinical Trials

Value in health, 2012-06, Vol.15 (4), p.A200-A200

2012

Link zum Volltext

Verfügbarkeit prüfen

MT61 Differences and Similarities of Health Economic Evaluation for Medical Technologies By HTA Bodies

Value in health, 2023-12, Vol.26 (12), p.S438

2023

Link zum Volltext

Verfügbarkeit prüfen

MT43 Does Real-World Evidence Play a Role in Decision-Making by HTA Bodies for Medical Technologies?

Value in health, 2023-12, Vol.26 (12), p.S434-S435

2023

Link zum Volltext

Verfügbarkeit prüfen

MT25 What Evidence Should Medical Technology Companies Expect HTA Bodies to Review?

Value in health, 2023-12, Vol.26 (12), p.S431

2023

Link zum Volltext

Verfügbarkeit prüfen

MT13 Digging into the Medical Technology HTA Process in Tunisia

Value in health, 2023-12, Vol.26 (12), p.S429

2023

Link zum Volltext

Verfügbarkeit prüfen

MT44 Submission Process and Requirements of Nordic Health Technology Assessment Organisations for Medical Technologies: Results of an Online Survey

Value in health, 2023-12, Vol.26 (12), p.S435

2023

Link zum Volltext

Verfügbarkeit prüfen

MT29 Understanding How Health Technology Assessment Bodies Select Medical Technology for Review: Results of an Online Survey

Value in health, 2023-12, Vol.26 (12), p.S432

2023

Link zum Volltext

Verfügbarkeit prüfen

Surgical Innovation: Do We Need A More Balanced Framework For Evidence?

Value in health, 2013-05, Vol.16 (3), p.A247-A247

2013

Link zum Volltext

Verfügbarkeit prüfen

MT16 What Is the Medical Technology HTA Process in Japan?

Value in health, 2024-06, Vol.27 (6), p.S284-S284

2024

Link zum Volltext

Verfügbarkeit prüfen

MT26 HTA Requirements for Medical Technologies in Canada

Value in health, 2024-06, Vol.27 (6), p.S286-S286

2024

Link zum Volltext

Verfügbarkeit prüfen

PSU36 Evidence Based Medicine: A Case Study of its Application to Innovative Surgical Procedures in the UK

Value in health, 2012-11, Vol.15 (7), p.A408-A408

2012

Link zum Volltext

Verfügbarkeit prüfen

Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial

American journal of clinical dermatology, 2003, Vol.4 (2), p.131-139

2003

Link zum Volltext

Verfügbarkeit prüfen

PMD44 Assessing Performance Following Primary Total Knee Arthroplasty (TKA): Development of the Patient'S Knee Implant Performance (PKIP) Measure

Value in health, 2012-06, Vol.15 (4), p.A70-A70

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(69)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

FDA PATIENT-REPORTED OUTCOME LABELING OF NOVEL THERAPIES (2011-2015)

United States decision maker perceptions of data from observational studies and other Health Economics and outcomes research

Evidence-Based Medicine, Appropriate-Use Criteria, and Sports Medicine: How Best to Develop Meaningful Treatment Guidelines

PNS226 A CONSOLIDATED FRAMEWORK FOR COLLABORATION IN RWE GENERATION FOR A MEDICAL PRODUCT

PCR74 Trends in the Inclusion of Patient Reported Outcomes in Oncology Clinical Trials: Analysis of ClinicalTrials.gov (2013-2022)

PRM111 Pediatric Patient-Reported Outcomes Assessment: A Case Study in Epidermolysis Bullosa

Payer Needs In Emerging Markets: How Should These Needs Be Included In Dermatology Drug Development Plans?

“Safe And Effective” Versus “Reasonable And Necessary”: Is The Deck Stacked Against Devices?

Psychometric Evaluation Of The Patient's Knee Implant Performance (PKIP) Questionnaire For The Assessment Of Primary Total Knee Arthroplasty

PHP182 Concordance of PRO Labeling Claims Between the FDA and EMA

Psychometric Evaluation Of The Psoriasis Symptom Diary Using Phase 3 Trial Data

PIH53 Assessment of PRO Labels Claims Granted by the FDA as Compared to the EMA

PIH49 Patient Reported Outcomes as Primary Endpoints in Confirmatory Clinical Trials

MT61 Differences and Similarities of Health Economic Evaluation for Medical Technologies By HTA Bodies

MT43 Does Real-World Evidence Play a Role in Decision-Making by HTA Bodies for Medical Technologies?

MT25 What Evidence Should Medical Technology Companies Expect HTA Bodies to Review?

MT13 Digging into the Medical Technology HTA Process in Tunisia

MT44 Submission Process and Requirements of Nordic Health Technology Assessment Organisations for Medical Technologies: Results of an Online Survey

MT29 Understanding How Health Technology Assessment Bodies Select Medical Technology for Review: Results of an Online Survey

Surgical Innovation: Do We Need A More Balanced Framework For Evidence?

MT16 What Is the Medical Technology HTA Process in Japan?

MT26 HTA Requirements for Medical Technologies in Canada

PSU36 Evidence Based Medicine: A Case Study of its Application to Innovative Surgical Procedures in the UK

Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial

PMD44 Assessing Performance Following Primary Total Knee Arthroplasty (TKA): Development of the Patient'S Knee Implant Performance (PKIP) Measure

Suchergebnisse filtern